Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 18
Summary
- Conditions
- Phase 1: Advanced or Refractory Solid Tumours
- Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin Cancer
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT01861496
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Ulrik Lassen, Professor MD, Ph.D Rigshospitalet, Finsen Centre, Oncology Department, Phase 1 Unit Principal Investigator: Dorte Nielsen, Professor MD, Ph.D Herlev&Gentofte Hospital, Oncology Department